Cognitive-behavioral Therapy for the Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.
NCT06939465 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2025-04-29
Summary
Gastroesophageal reflux disease (GERD) is a challenging gastrointestinal disorder, and proton pump inhibitors (PPIs) are typically the first line of treatment. However, up to 40% of GERD patients experience little to no relief or only partial relief of their symptoms after receiving PPI therapy. Among these patients, who do not respond to high-dose PPIs taken twice daily, more than 90% exhibit conditions related to brain-gut axis communication disorders, such as esophageal hypersensitivity and functional heartburn. Visceral hypersensitivity and esophageal hypervigilance are the two key causes of esophageal symptoms in this group of patients. According to the Rome IV consensus on esophageal disorders, five categories are identified: functional chest pain, functional heartburn, globus sensation, functional dysphagia, and esophageal hypersensitivity. The diagnostic criteria state that patients must have chronic esophageal symptoms, and any structural, inflammatory, or motility abnormalities must be excluded. Therefore, diagnosing brain-gut axis communication disorders in the esophagus requires upper gastrointestinal endoscopy, esophageal pH-impedance testing, and high-resolution esophageal manometry. Neuromodulators, which regulate peripheral and central pain sensitivity, are a cornerstone of pharmacological treatment for brain-gut axis communication disorders and associated symptoms. Additionally, growing evidence supports the use of brain-gut axis behavioral therapies, such as gut-directed hypnotherapy and cognitive behavioral therapy (CBT), to effectively treat these disorders. However, research on neuromodulators and CBT in brain-gut axis communication disorders remains limited, and their efficacy is still unclear. The aim of this study is to investigate the effectiveness and role of CBT in treating brain-gut axis communication disorders. The information gained from this research will help clarify the pathophysiological mechanisms related to brain-gut axis communication abnormalities and refractory GERD symptoms. Furthermore, the findings will guide the development of effective treatment strategies for patients with brain-gut axis communication disorders who do not respond to PPI therapy in clinical practice.
Conditions
- Gut-Brain Disorders
- GERD Without Erosive Esophagitis
Interventions
- BEHAVIORAL
-
Cognitive Behavioral Therapy (CBT)
The participants will undergo a 6-week cognitive behavioral therapy (CBT) guided by a psychologist, with one session per week, each lasting 1 hour.
- BEHAVIORAL
-
Lifestyle management (sham control)
The participants will undergo a 6-week lifestyle management (sham control) guided by a psychologist, with one session per week, each lasting 1 hour.
Sponsors & Collaborators
-
Hualien Tzu Chi General Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-04-02
- Primary Completion
- 2025-04-24
- Completion
- 2025-12-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Predictors of Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease Patients
NCT01797939 ·Status: COMPLETED
-
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
NCT01472939 ·Status: COMPLETED ·Phase: PHASE2
-
The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients
NCT02149914 ·Status: UNKNOWN ·Phase: NA
-
Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication
NCT02934152 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of PPI in Preventing Gastroesophageal Reflux Disease of Seafarers
NCT04696783 ·Status: UNKNOWN ·Phase: PHASE3
-
The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Sensitivity in Healthy Volunteers
NCT02674256 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease
NCT03436914 ·Status: COMPLETED ·Phase: NA
-
Correlates of GERD Symptom Severity
NCT03020550 ·Status: COMPLETED
-
Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy
NCT03596476 ·Status: RECRUITING ·Phase: NA
-
Combined Scalp and Ear Acupuncture in Patients With Proton Pump Inhibitor- Dependent Gastroesophageal Reflux Disease
NCT04660019 ·Status: COMPLETED ·Phase: NA
-
Endoscopic Findings in Patients With Typical Gastroesophageal Reflux Disease (GERD) Symptoms
NCT00730106 ·Status: COMPLETED
-
The Influence of Hypnotic Medications on Sleep Arousal and Its Effect on Gastroesophageal Reflux
NCT00462137 ·Status: COMPLETED
-
"The Voice of Reflux" - Backflow of Gastric Juice Leads to Irritation of the Vocal Folds: Are There Typical Differences in the Voice?
NCT06495606 ·Status: RECRUITING
-
Outcomes for Patients With Gastro-Esophageal Reflux Disease
NCT03824548 ·Status: UNKNOWN
-
The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department
NCT02506634 ·Status: COMPLETED
-
Effective Mechanisms of Wu-Chu-Yu Tang on Gastroesophageal Disorder
NCT04118647 ·Status: UNKNOWN ·Phase: PHASE4
-
A Comparison of Factors of Symptoms Generation and Evaluation of Role of Biofeedback in Patients With Different Types of Functional Esophageal Disorders (Functional Heartburn and Functional Chest Pain)
NCT00471796 ·Status: UNKNOWN ·Phase: NA
-
Sleep Disorders and Gastroesophageal Reflux Disease (GERD)
NCT00287391 ·Status: COMPLETED ·Phase: PHASE4
-
Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence
NCT04255693 ·Status: RECRUITING ·Phase: NA
-
Response to Supplement and Placebo in GERD
NCT01915173 ·Status: COMPLETED ·Phase: NA
-
Retrospective Observational Study on GERD Management in General Hospitals in Korea
NCT06974903 ·Status: COMPLETED
-
The Potential Therapeutic Effect of Melatonin in Gastro-Esophageal Reflux Disease
NCT00915616 ·Status: WITHDRAWN ·Phase: PHASE3
-
Determining Risk Factors for Successful PPI Weaning
NCT03226054 ·Status: TERMINATED ·Phase: NA
-
The Influence of Concomitant Irritable Bowel Syndrome on Gastro-Oesophageal Reflux Disease Symptoms and Severity.
NCT06615856 ·Status: NOT_YET_RECRUITING
-
Effect of Citalopram on Reflux Episodes in Healthy Volunteers
NCT03746691 ·Status: COMPLETED ·Phase: PHASE4